Moreover, when the serum levels of Gal1 were compared in ovarian cancer patients alongside the most widely used biomarker CA125, it was found that around 70% of patients were correctly identified as positive by both proteins [19], suggesting that Gal1 could potentially be used as a biomarker for HGSC progression, as well as outcome. Here, LGALS1 is linked to ovarian carcinoma.